Clinical trials: Intravenous Administration
Neoplasms
Exploration of Tumor Accumulation of BAY94-9392 in Patients With Cancer
The study will be conducted as an open label, single-dose, explorative study with patients with histologically proven cancer and, preferably, tumor positive lesions in previously performed nuclear medicine imaging examinations.
- Trial name
- NCT01186601
- Testing
- PET tracer (BAY94-9392)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Lantheus Biosciences Ltd.
Symptomatic Anemia
A Study in Healthy Volunteers to Compare the Profiles of DA-3880 and EU Sourced ARANESP® (Amgen)
The main purpose of the study is to determine whether the test product and the reference product are bioequivalent based on the pharmacokinetics after administration of ug/kg as a single intravenous dose and as a single…
- Trial name
- NCT02241200
- Testing
- DA3880, Aranesp
- Where
- Netherlands
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Dong-A ST Co., Ltd.
Acute Bacterial Skin and Skin Structure Infection
Study to Evaluate the Safety of Intravenous Oritavancin for the Treatment of Children With Skin Infections
This protocol describes a randomized, open-label study to evaluate the safety and tolerability of 2 formulations of single-dose intravenous (IV) oritavancin diphosphate (Orbactiv and Kimyrsa) for the treatment of pediatric…
- Trial name
- NCT05599295
- Testing
- Orbactiv, Kimyrsa
- Where
- 23 sites in United States, Bulgaria and 6 more
- Volunteers
- 118 people
- Sponsor
- Melinta Therapeutics, LLC
PORTs/Peripheral IVs Complication Rates
Post-Marketing Study to Assess Complication Rates of Oncology Patients With Ports and Peripheral IVs
This study is to collect current information on complications rates of subjects undergoing chemotherapy administration through Ports and peripheral IVs.
- Trial name
- VEINSFORLIFE (NCT02792764)
- Where
- 2 sites in United States
- Volunteers
- 300 people
- Sponsor
- C. R. Bard
Myocardial Infarction
MiSaver® Stem Cell Treatment for Heart Attack (Acute Myocardial Infarction)
The objective of the present study is to establish the safety and efficacy of MiSaver® Stem Cell Treatment After a Heart Attack (Acute Myocardial Infarction)
- Trial name
- MiSaver® (NCT04050163)
- Testing
- MiSaver®
- Where
- 2 sites in Taiwan
- Volunteers
- 11 people
- Sponsor
- Honya Medical Inc
Subjects Treated With Busulfan
Busulfan Sample Collection Study
Busulfan (Busulfex®) is an alkylating drug used as a conditioning regimen prior to allogeneic hematopoietic stem cell transplantation.
- Trial name
- NCT05711732
- Testing
- MyCare Oncology Busulfan Assay Kit
- Where
- 3 sites in United States
- Volunteers
- 150 people
- Sponsor
- Saladax Biomedical, Inc.
Healthy Participants
Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Infusion of XTMAB-16 in Healthy Adult Participants
This is a single-center, randomized, double-blind, placebo-controlled, first-in-human, single intravenous (IV) infusion of XTMAB-16 (formerly referred to as KBMAB-16) in normal healthy male and female participants.
- Trial name
- NCT04971395
- Testing
- XTMAB-16 2 mg/kg, XTMAB-16 4mg/kg
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Xentria, Inc.
Myocardial Infarction
IRI-EXPLORE: A Study to Test Whether BI 765845 Helps People Who Have Had a Heart Attack
This study is open to adults aged 18 and over who have just had a heart attack. The purpose of this study is to find out whether a medicine called BI 765845 helps people who have had a heart attack.
- Trial name
- IRI-EXPLORE (NCT06139328)
- Testing
- BI 765845
- Where
- 53 sites in Australia, Canada and 12 more
- Volunteers
- 160 people
- Sponsor
- Boehringer Ingelheim
Generalized Myasthenia Gravis
Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia Gravis
The purpose of this study is to investigate the Pharmacodynamics (PD), Pharmacokinetics (PK), safety, tolerability, immunogenicity, and clinical efficacy of efgartigimod coformulated with recombinant human hyaluronidase PH20…
- Trial name
- ADAPTsc (NCT04735432)
- Testing
- efgartigimod PH20 SC, efgartigimod IV
- Where
- 47 sites in United States, Belgium and 9 more
- Volunteers
- 110 people
- Sponsor
- argenx
Healthy
Study to Evaluate the Effects of 90 mg Intravenous Infusions of GC4419 on the Single Dose Pharmacokinetics of Dextromethorphan in Healthy Adult Subjects
This will be a single center, phase 1, open-label, fixed-sequence study under fasting conditions to evaluate the effect of 90 mg intravenous (IV) infusions of GC4419 on the single-dose pharmacokinetic (PK) of dextromethorphan…
- Trial name
- NCT03792971
- Testing
- Dextromethorphan HBr, GC4419
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Galera Therapeutics, Inc.
Crohn's Disease (CD)
Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)
Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. This study will evaluate how well risankizumab works compared to ustekinumab.
- Trial name
- SEQUENCE (NCT04524611)
- Testing
- Risankizumab, Ustekinumab
- Where
- 300 sites in United States, Argentina and 29 more
- Volunteers
- 527 people
- Sponsor
- AbbVie
Acute Decompensated Heart Failure
Efficacy and Safety of Ularitide for the Treatment of Acute Decompensated Heart Failure
The purpose of this study is to evaluate the efficacy and safety of a continuous intravenous (IV) ularitide infusion on the clinical status and outcome of patients with acute decompensated heart failure (ADHF).
- Trial name
- TRUE-AHF (NCT01661634)
- Testing
- Ularitide
- Where
- 163 sites in United States, Argentina and 20 more
- Volunteers
- 2,157 people
- Sponsor
- Cardiorentis
Crohn's Disease
Vedolizumab Intravenous (IV) Compared to Placebo in Chinese Participants With Crohn's Disease.
The purpose of this study is to assess the safety and efficacy of vedolizumab intravenous (IV) infusion as induction treatment in Chinese participants with moderately to severely active Crohn's disease (CD) at Week 10.
- Trial name
- NCT03234907
- Testing
- Vedolizumab IV
- Where
- 29 sites in China
- Volunteers
- 215 people
- Sponsor
- Takeda
Healthy
Absorption, Metabolism, and Excretion Study of [14C]-TNP-2092
This is an open-label, single dose, Phase 1 study conducted at a single study center in the United States (USA). This study will evaluate the absorption, metabolism and elimination (AME), mass balance, safety and tolerability of…
- Trial name
- NCT05074134
- Testing
- [14C]-TNP-2092
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- TenNor Therapeutics Limited
Fungal Infection
Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects
First In Human (FIH), randomized, double-blind, placebo-controlled single ascending dose (SAD) and multiple ascending dose (MAD) escalation study of approximately 80 subjects.
- Trial name
- NCT02956499
- Testing
- APX001 single dose 1, APX001 single dose 2, APX001 single dose 3
- Where
- 2 sites in Netherlands
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Basilea Pharmaceutica
Lymphoma, Non-Hodgkin
A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18
The purpose is to identify a dose of SB-485232 which is safe, tolerable and effective when used in combination with Rituximab in patients with non-Hodgkin's lymphoma (NHL).
- Trial name
- NCT00500058
- Testing
- SB-485232, Rituximab
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- GlaxoSmithKline
Complex Regional Pain Syndrome Type I
Phase 3, Open-Label Extension Study of AMBTX-01 (Neridronate) for Complex Regional Pain Syndrome Type 1
A Phase 3 open-label extension study of AMBTX-01 (neridronate) for Complex Regional Pain Syndrome Type 1
- Trial name
- NCT07857733
- Testing
- Neridronate
- Where
- United States
- Volunteers
- 135 people
- Sponsor
- Ambros Therapeutics, Inc.
Healthy Adult Male
A Phase I, Open-Label Trial to Assess the Absorption, Metabolism, and Excretion of (14C)-OPC-61815 in Healthy Male Japanese Subjects
To determine the mass balance of totalradioactivity following a single IV infusionof (14C)-OPC-61815. To determine routes and rates of elimination of total radioactivity following a single IV infusion of (14C)-OPC-61815 To assess…
- Trial name
- NCT04182958
- Testing
- (14C)-OPC-61815
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Pain, Fever
Safety and Pharmacokinetic Study of Intravenous Ibuprofen in Pediatric Patients
The primary objective of this study is to evaluate the pharmacokinetic profile of a single dose of intravenous ibuprofen administered over approximately ten (10) minutes.
- Trial name
- NCT02583399
- Testing
- Ibuprofen
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Cumberland Pharmaceuticals
Stroke
Cytoflavin in the Complex Rehabilitation of Stroke Patients
It is known that the acute period of stroke occurs is accompanied by oxidative stress, when intense generation of reactive oxygen species (ROS) have a toxic effect, which causes oxidative degradation of proteins, lipids, nucleic…
- Trial name
- NCT05935787
- Testing
- Cytoflavin (Inosine + Nicotinamide + Riboflavin + Succinic Acid)
- Where
- 3 sites in Russia
- Volunteers
- 240 people
- Sponsor
- POLYSAN Scientific & Technological Pharmaceutical Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.